Roy Amariglio is an observer on GentiBio board of directors and Principal on the Israel team for OrbiMed Advisors LLC, a healthcare investment firm, covering venture capital investments in biotech, medical device, and diagnostics companies. Prior to joining OrbiMed, he was a Director of Mergers, Acquisitions, and Licensing at Bayer HealthCare where he was responsible for Healthcare transactions. While at Bayer, he held several positions of increasing responsibilities in Oncology Marketing and Business Development. Roy received his B.A. in Chemistry and Biology from Tel Aviv University and an M.Sc. and Ph.D. in Molecular Genetics from the Weizmann Institute in Israel, as well as an M.B.A. in Finance and Healthcare Management from the Wharton School of the University of Pennsylvania.

Andrew Levin is Board Director on GentiBio Board of Directors. Andrew is a Managing Director and co-leads the Venture Team at RA Capital Management, a healthcare and life sciences focused investment firm. Prior to joining RA, he was a Vice President at H.I.G. BioVentures and served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He received a B.S.E in Mechanical Engineering from Princeton University, a Ph.D. in Biomedical Engineering from the Massachusetts Institute of Technology, and an M.D. from Harvard Medical School.

Nandita Shangari is a Board Observer, and Managing Partner at the Novartis Venture Fund (NVF), a life science investment firm. Prior to joining NVF, she held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah® Global Program Team, helping to bring this novel cell therapy to market.Nandita also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization. She received a B.Sc. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada

Abhiram Rao is a GentiBio Board Observer and Vice President at Matrix Capital, a technology and life sciences investment firm. In addition to GentiBio, he is a Board Observer at Maze Therapeutics, AltPep and nference. Prior to Matrix, he held roles in strategy and R&D at Tempus, Illumina, and startups in biotechnology and genomics. Abhiram holds a PhD in Bioengineering from Stanford University where his research focused on early-stage drug discovery leveraging computational and high-throughput experimental technologies. He is an author on over 30 papers in journals including Science and Nature Genetics.

Andy Tran is a GentiBio Board Director and a Vice President that leads and oversees key private biotechnology investments at Matrix Capital, a technology and life sciences investment firm. In addition to GentiBio, he has led investments in and served on the boards of multiple companies including Scribe Therapeutics, Insitro, EQRx, Dyno, and other startups in stealth-mode. Prior to Matrix, he was an Investment Partner at Andreesen Horowitz’s (a16z) Bio Fund investing in early-stage ventures in the life sciences. He has previously held roles at Genentech’s Discovery Oncology R&D department and Morgan Stanley’s investment banking group. Andy was trained as a Bioengineer and Computer scientist at Harvard University, where his research focused on gene therapy and CRISPR genome engineering technologies.

Nathaniel Brooks Horwitz is a GentiBio Board Observer and Principal at RA Capital Management, a healthcare and life sciences investment firm. He has served as a Director or Observer on the boards of several RA Capital portfolio companies, including Quench Bio, Eliem Therapeutics, Clear Creek Bio, and multiple stealth-mode ventures. He was previously CEO of Nivien Therapeutics. His writing on biotech and other subjects has been published by The Washington Post, The New York Times, The Atlantic, The Boston Globe, and The Financial Review. Horwitz received an A.B. in Molecular and Cellular Biology from Harvard University.

Michal Silverberg is a GentiBio Board Director and a Managing Director at the Novartis Venture Fund (NVF), a life science investment firm. Prior to joining NVF, she was a Senior Partner at Takeda Ventures and, before that, held roles of increasing responsibility at Novo Nordisk, including Senior Director of Business Development and New Product Commercialization. Since 1998, Michal has held positions in various sectors of the life science industry, including in the Office of the Chief Scientist of Israel, venture capital, and global pharmaceutical and biotech companies. She received her B.A. in Economics and Business Management from Haifa University, her M.B.A from Tel-Aviv University, and her M.S. in Biotechnology from Columbia University.

Carl Gordon is a member of the Board of Directors. Carl is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm.  He also  serves on the boards of directors of several public and private companies.  Carl received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a fellow at The Rockefeller University.

Erez Chimovits is Chairman of the GentiBio Board of Directors. Erez is a Partner and Senior Managing Director on the Israel team for OrbiMed Advisors LLC, a healthcare investment firm. Erez has 14-years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, Erez was the CEO of NasVax. Previously, Erez spent more than seven years with Compugen as President of Compugen USA Inc. and Executive VP of Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex, and others. Erez earned his B.Sc., his M.B.A., and his M.Sc. in Microbiology from Tel Aviv University.

Adel Nada is Co-founder and Chief Executive Officer of GentiBio. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics where he worked on advancing engineered regulatory T cell (Tregs) therapeutics. In the past, Adel has held executive positions in various biotech and pharmaceutical companies, including Vice President at Intellia Therapeutics and Caladrius Biosciences, and various senior positions directing clinical development at Baxter and Abbott. He successfully led translational immunology programs over past 15 years for experimental and approved therapies, spanning small and large molecules and engineered immune cell products, including Tregs products. Adel received his medical degree from Alexandria University in Egypt and his master’s degree in Clinical Research from the Pharmacology Dept. at Rush University in Chicago where he also held an academic position. Adel completed advanced studies in drug development at UCSF and University of Basel before becoming a Member of the Faculty of Pharmaceutical Medicine in the UK. Prior to joining the industry, Adel trained in surgery and internal medicine and practiced for 10 years in Chicago. When not preoccupied with Tregs and inflammation, he focuses his constant curiosity on reading and exploring new people, ideas and places. Adel also enjoys long distance running, street photography, and meditation.